Cargando…
A benefit–risk analysis of rotavirus vaccination, France, 2015
Two vaccines available for protection against rotavirus gastroenteritis (RVGE), Rotarix and RotaTeq, have contributed to a large decrease in the incidence of paediatric diarrhoea in countries where they have been used. However, they have also led to a small increase in the risk of intussusception. M...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Centre for Disease Prevention and Control (ECDC)
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743099/ https://www.ncbi.nlm.nih.gov/pubmed/29258644 http://dx.doi.org/10.2807/1560-7917.ES.2017.22.50.17-00041 |
_version_ | 1783288507736784896 |
---|---|
author | Lamrani, Adnane Tubert-Bitter, Pascale Hill, Catherine Escolano, Sylvie |
author_facet | Lamrani, Adnane Tubert-Bitter, Pascale Hill, Catherine Escolano, Sylvie |
author_sort | Lamrani, Adnane |
collection | PubMed |
description | Two vaccines available for protection against rotavirus gastroenteritis (RVGE), Rotarix and RotaTeq, have contributed to a large decrease in the incidence of paediatric diarrhoea in countries where they have been used. However, they have also led to a small increase in the risk of intussusception. Methods: We compare the number of prevented hospitalisations for RVGE to the number of vaccine-induced hospitalised intussusceptions in France. Results: With 9.5% coverage (French 2015 estimation), vaccination was estimated to prevent, annually, a median of 1,074 hospitalisations (2.5th and 97.5th percentiles (2.5th–97.5th): 810–1,378) and 1.4 deaths (2.5th–97.5th: 1.2–1.6) from RVGE. It was also estimated to cause, annually, 5.0 hospitalisations (2.5th–97.5th: 3.2–7.7) and 0.005 deaths (2.5th–97.5th: 0.001–0.015) from intussusception. The benefit–risk ratio is therefore 214 (2.5th–97.5th: 128–362) for hospitalisations and 273 (2.5th–97.5th: 89–1,228) for deaths. Under a hypothetical 92% coverage, rotavirus vaccination with Rotarix would avoid 10,459 (2.5th–97.5th: 7,702–13,498) hospitalisations for RVGE and induce 47.0 (2.5th–97.5th: 25.1–81.4) hospitalisations for intussusception annually, thereby preventing 13.7 (2.5th–97.5th: 11.1–15.2) deaths and inducing 0.05 (2.5th–97.5th: 0.01–0.15) deaths. Conclusion: The benefit–risk ratio in France is similar to that of other European countries. |
format | Online Article Text |
id | pubmed-5743099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | European Centre for Disease Prevention and Control (ECDC) |
record_format | MEDLINE/PubMed |
spelling | pubmed-57430992018-01-02 A benefit–risk analysis of rotavirus vaccination, France, 2015 Lamrani, Adnane Tubert-Bitter, Pascale Hill, Catherine Escolano, Sylvie Euro Surveill Research Article Two vaccines available for protection against rotavirus gastroenteritis (RVGE), Rotarix and RotaTeq, have contributed to a large decrease in the incidence of paediatric diarrhoea in countries where they have been used. However, they have also led to a small increase in the risk of intussusception. Methods: We compare the number of prevented hospitalisations for RVGE to the number of vaccine-induced hospitalised intussusceptions in France. Results: With 9.5% coverage (French 2015 estimation), vaccination was estimated to prevent, annually, a median of 1,074 hospitalisations (2.5th and 97.5th percentiles (2.5th–97.5th): 810–1,378) and 1.4 deaths (2.5th–97.5th: 1.2–1.6) from RVGE. It was also estimated to cause, annually, 5.0 hospitalisations (2.5th–97.5th: 3.2–7.7) and 0.005 deaths (2.5th–97.5th: 0.001–0.015) from intussusception. The benefit–risk ratio is therefore 214 (2.5th–97.5th: 128–362) for hospitalisations and 273 (2.5th–97.5th: 89–1,228) for deaths. Under a hypothetical 92% coverage, rotavirus vaccination with Rotarix would avoid 10,459 (2.5th–97.5th: 7,702–13,498) hospitalisations for RVGE and induce 47.0 (2.5th–97.5th: 25.1–81.4) hospitalisations for intussusception annually, thereby preventing 13.7 (2.5th–97.5th: 11.1–15.2) deaths and inducing 0.05 (2.5th–97.5th: 0.01–0.15) deaths. Conclusion: The benefit–risk ratio in France is similar to that of other European countries. European Centre for Disease Prevention and Control (ECDC) 2017-12-14 /pmc/articles/PMC5743099/ /pubmed/29258644 http://dx.doi.org/10.2807/1560-7917.ES.2017.22.50.17-00041 Text en This article is copyright of The Authors, 2017. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made. |
spellingShingle | Research Article Lamrani, Adnane Tubert-Bitter, Pascale Hill, Catherine Escolano, Sylvie A benefit–risk analysis of rotavirus vaccination, France, 2015 |
title | A benefit–risk analysis of rotavirus vaccination, France, 2015 |
title_full | A benefit–risk analysis of rotavirus vaccination, France, 2015 |
title_fullStr | A benefit–risk analysis of rotavirus vaccination, France, 2015 |
title_full_unstemmed | A benefit–risk analysis of rotavirus vaccination, France, 2015 |
title_short | A benefit–risk analysis of rotavirus vaccination, France, 2015 |
title_sort | benefit–risk analysis of rotavirus vaccination, france, 2015 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743099/ https://www.ncbi.nlm.nih.gov/pubmed/29258644 http://dx.doi.org/10.2807/1560-7917.ES.2017.22.50.17-00041 |
work_keys_str_mv | AT lamraniadnane abenefitriskanalysisofrotavirusvaccinationfrance2015 AT tubertbitterpascale abenefitriskanalysisofrotavirusvaccinationfrance2015 AT hillcatherine abenefitriskanalysisofrotavirusvaccinationfrance2015 AT escolanosylvie abenefitriskanalysisofrotavirusvaccinationfrance2015 AT lamraniadnane benefitriskanalysisofrotavirusvaccinationfrance2015 AT tubertbitterpascale benefitriskanalysisofrotavirusvaccinationfrance2015 AT hillcatherine benefitriskanalysisofrotavirusvaccinationfrance2015 AT escolanosylvie benefitriskanalysisofrotavirusvaccinationfrance2015 |